Cerebral vasodilatory capacity mapping using technetium-99m-DTPA-HSA SPECT and acetazolamide in moyamoya disease.
A cerebral vasodilatory capacity map, consisting of a 99mTc-DTPA-HSA SPECT image obtained after acetazolamide injection minus the baseline image, was produced in a patient with moyamoya disease. The map demonstrated diminished capacity in the posterior region of the right cerebral hemisphere. Subsequently, cerebral infarction occurred in the corresponding area. This observation suggests that regions of low vasodilatory capacity identified by cerebral vasodilatory capacity mapping may be at high risk of ischemic stroke.
Inoue
Y
Y
Department of Radiology, Saitama Medical Center, Saitama Medical School, Japan.
Momose
T
T
Machida
K
K
Honda
N
N
Tsutsumi
K
K
D000086:Acetazolamide / Q000494:pharmacology*; D002544:Cerebral Infarction / Q000175:diagnosis / Q000209:etiology; D002560:Cerebrovascular Circulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009072:Moyamoya Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000503:physiopathology; D013668:Technetium Tc 99m Aggregated Albumin; D016284:Technetium Tc 99m Pentetate; D015899:Tomography, Emission-Computed, Single-Photon; D014664:Vasodilation / Q000187:drug effects*
D013668:Technetium Tc 99m Aggregated Albumin; C057162:technetium Tc 99m DTPA HSA; D000086:Acetazolamide; D016284:Technetium Tc 99m Pentetate